LCM
NRIX icon

Laurion Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Laurion Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-28,470
Closed -$399K – 638
2022
Q1 		$399K Buy
+28,470
New +$505K ﹤0.01% 404
2021
Q2 		– Sell
-7,000
Closed -$218K – 878
2021
Q1 		$218K Hold
7,000
– – ﹤0.01% 685
2020
Q4 		$230K Hold
7,000
– – ﹤0.01% 572
2020
Q3 		$244K Buy
+7,000
New +$176K ﹤0.01% 717

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Laurion Capital Management's NRIX Position: Q2 2022 in Review

Laurion Capital Management sold out of Nurix Therapeutics (NRIX) in Q2 2022, closing a stake of 28,470 shares — an estimated $399K sold.

Laurion Capital Management first reported a position in NRIX in Q3 2020 and held it in 4 quarters. The position peaked at $399K in Q1 2022. 106 funds tracked by Wall St. Rank hold NRIX as of Q2 2022.

  • Laurion Capital Management reported no remaining Nurix Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Laurion Capital Management sold 28,470 Nurix Therapeutics shares in Q2 2022, an estimated $399K.
  • Laurion Capital Management first reported a position in Nurix Therapeutics in Q3 2020 and held it in 4 quarters.
  • Laurion Capital Management's Nurix Therapeutics position peaked at $399K in Q1 2022.
  • 106 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.